Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya30642Editorial articleПередовая статьяMechanisms of phosphorus and calcium homeostatic disorders in the development of cardiovascular events in patients with chronic renal diseases. The role of fibroblast growth factor 23 and KlothoМеханизмы нарушения фосфорно-кальциевого гомеостаза в развитии сердечно-сосудистых осложнений у больных хронической болезнью почек. Роль фактора роста фибробластов-23 (FGF-23) и KlothoMilovanovaL YuМиловановаЛюдмила Юрьевна

I. M. Sechenov Moscow Medical Academy

канд. мед. наук, науч. сотр., отд-ние нефрологии НИЦ; Московская медицинская академия им. И. М. Сеченова

Lussya2000@mail.ruKozlovskayaL VКозловскаяЛидия Владимировна

I. M. Sechenov Moscow Medical Academy

д-р мед. наук, проф., каф. терапии и профболезней; Московская медицинская академия им. И. М. Сеченова

MilovanovYu SМиловановЮрий Сергеевич

I. M. Sechenov Moscow Medical Academy

д-р мед. наук, вед. науч. сотр., отд. нефрологии НИЦ; Московская медицинская академия им. И. М. Сеченова

yumil2010@rambler.ruBobkovaI NБобковаИрина Николаевна

I. M. Sechenov Moscow Medical Academy

д-р мед. наук, зав., отд. нефрологии НИЦ; Московская медицинская академия им. И. М. Сеченова

irbo.mma@mail.ruDobrosmyslovI AДобросмысловИгорь Александрович

I. M. Sechenov Moscow Medical Academy

зав., отд-ние гемодиализа; Московская медицинская академия им. И. М. Сеченова

I. M. Sechenov Moscow Medical AcademyМосковская медицинская академия им. И. М. Сеченова15062010826NO6 (2010)ТОМ 82, №6 (2010)667209042020Copyright ©; 2010, Consilium MedicumCopyright ©; 2010, ООО "Консилиум Медикум"2010Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/30642

The paper deals with the analysis of studies of the role of the bone morphogenetic proteins fibroblast growth factor 23 (FGF-23) and Klothno in the development of vascular wall calcification in chronic renal disease (CRD). FGF-23 is shown to be an important phosphaturic hormone that inhibits hypercalcemic and hyperphosphatemic effects of elevated serum vitamin D concentrations. There is evidence that there is an association between high serum FGF-23 levels and vascular wall calcification irrespective of the content of phosphorus and parathyroid hormone. Most authors regard FGF-23 as a potential uremic toxin in patients with end-stage CRD. There are data that support the renoprotective value of the morphogenetic protein Klotho whose expression in CRD is decreased.

Статья посвящена анализу исследований по изучению роли костных морфогенетических белков FGF-23 и Klotho в развитии кальцификации сосудистой стенки при хронической болезни почек (ХБП). Показано, что FGF-23 является важным фосфатурическим гормоном, препятствующим гиперкальциемическому и гиперфосфатемическому эффектам повышенной концентрации витамина D в сыворотке. Подтверждена связь высокого уровня FGF-23 в сыворотке и кальцификации сосудистой стенки независимо от уровня фосфора и паратиреоидного гормона. Большинство авторов рассматривают FGF-23 в качестве потенциального "уремического токсина" у пациентов с терминальной стадией ХБП. Получены данные, подтверждающие ренопротективное значение морфогенетического белка Klotho, экспрессия которого при ХБП снижена.

chronic heart diseasehyperphosphatemiacalcificationmorphogenetic proteinsхроническая болезнь почекгиперфосфатемиякальцификацияморфогенетические белкиZhang Qiu-Li, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Publ. Hlth 2008; 8: 117.Coresh J., Selvin E., Stevens L. A. et al. Prevalence of chronic kidney disease in the United States. J. A. M. A. 2007; 298: 2038-2047.Hruska K. A., Mathew S., Lund R. et al. Author manuscript; available in PMC 2009. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008; 74 (2): 148-157.Foley R. N., Parfrey P. S., Sarnak M. J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998; 32: S112-S119.London G. M. Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol. Dial. Transplant. 2000; 15 (suppl. 5): 97-104.Go A. S., Chertow G. M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-1305.Sarnak M. J., Levey A. S., Schoolwerth A. C. et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.Wright J., Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vasc. Hlth Risk Manag. 2009; 5: 713- 722.Locatelli F., Marcelli D. et al. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol. Dial. Transplant. 2000; 15 (suppl. 5): 69-80.Parfey P. S. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol. Dial. Transplant. 2001; 15 (suppl. 5): 58-68.Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin. Dial. 2003; 16 (2): 101-105.Gutiérrez O. M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.Block G. A., Hulbert-Shearon T. E., Levin N. W. et al. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998; 31: 607-617.Kestenbaum B., Sampson J. N., Rudser K. D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 520-528.Westerberg P. A. et al. Regulation FGF-23 in CKD. Nephrol. Dial. Transplant. 2007; 22 (11): 3202-3207.Nakanishi S. et al. Serum FGF-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005; 68 (1): 410-411.Yean G. et al. High levels of serum FGF-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 2009; 24 (9): 2792-2796.Gutiérrez O. M., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 359: 584-592.Makoto K. Klotho in chronic kidney disease. What's new? Nephrol. Dial. Transplant. 2009; 24 (6): 1705-1708.Ramon I. et al. FGF-23 and its role in phosphate homeostasis. Eur. J. Endocrinol. 2010; 162(1): 1-10.Shigematsu T. et al. Possible involvement of circulating FGF-23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 2004; 44 (2): 250-256.Razzaque M. S. Does FGF-23 toxicity influence the outcome of chronic kidney disease? Nephrol. Dial. Transplant. 2009; 24 (1): 4-7.Marchais S. J., Metivier F., Guerin A. P. et al. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol. Dial. Transplant. 1999; 14: 2178-2183.Craver L., Marco M. P., Martinez I. et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 - achievement of K/DOQI target ranges. Nephrol. Dial. Transplant. 2007; 22: 1171-1176.Davies M. R., Lund R. J., Mathew S. et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J. Am. Soc. Nephrol. 2005; 16: 917-928.Jono S., McKee M. D., Murry C. E. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 2000; 87: 10-17.Guillaume J. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol. Dial. Transplant. 2009; 24 (3): 948-955.Raggi P., Boulay A., Chasan-Taber S. et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J. Am. Coll. Cardiol. 2002; 39: 695-701.London G. M., Guerin A. P., Marchais S. J. et al. Arterial media calcification in end-stage renal diseases: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 2003; 18: 1731-1740.Isakova T., Gutierrez O. et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J. Am. Soc. Nephrol. 2008; 19 (3): 615-623.